



XDx Files Reexamination Request for Source MDx Patent

BRISBANE, Calif.--(BUSINESS WIRE)-- February 15, 2008 - XDx, Inc., a molecular diagnostics company, announced today that it has filed an Inter Partes Reexamination requesting that the United States Patent and Trademark Office review certain claims of United States Patent No. 6,964,850 ("850 Patent") assigned to Source MDx, Inc., entitled "Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles." The '850 Patent purports to claim methods for creating an index of a subject's biological state pertaining to inflammation. XDx's request states that a combination of prior art references available before the '850 patent's earliest priority date raise substantial new questions about the patentability of certain of the patent's claims.

Founded in 2000, XDx is a molecular diagnostics company based in Brisbane, California. Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company has developed a proprietary new method for noninvasively monitoring the immune system by measuring gene expression in a patient's peripheral blood. The technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

About XDx

XDx's mission is to improve patient care by developing molecular diagnostics that translate an individual's immune status into clinically actionable information. XDx is a molecular diagnostics company that utilizes state-of-the-art genomic technology and sophisticated bioinformatics analyses to understand and measure the immune processes that underlie specific immune-mediated conditions. Physicians can use this information to optimize patient treatment and minimize the long-term consequences of immunosuppressive therapies. XDx's science and technology is now being evaluated in patients with solid organ transplants. Building on the discoveries made during the development of AlloMap® molecular expression testing for heart transplant patients, which included the identification of many genes and pathways involved in tissue rejection, XDx is now developing a product for use by physicians to better manage lung transplant patients. Beyond the use of AlloMap testing in assessing immune response in solid organ transplantation, XDx scientists are applying similar approaches to create new molecular diagnostic tests for the improved clinical

management of immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE or lupus), to diagnose and predict clinical flares common in a variety of these diseases.

Cautionary Note About Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: challenges inherent in the process of designing molecular expression tests for transplant monitoring, challenges associated with the incorporation of licensed technology into XDx's development process, developmental challenges posed by differences among various forms of transplant rejection and immune mediated diseases, our ability to increase usage of our tests, the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing test and any future tests we may develop, the risks and uncertainties associated with the regulation of our test, our ability to obtain capital when needed, our history of operating losses, and the results of our clinical studies. These forward-looking statements speak only as of the date hereof. XDx disclaims any obligation to update these forward-looking statements.

CONTACT:

Corporate:
Dirk Lammerts
XDx, Inc.
415-287-2300

Media:
Helene Ellison
HealthSTAR Public Relations
646-722-8808

###